Navigation Links
Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference

addressable patient populations, including second line hormone therapy candidates and second line chemotherapy candidates, continue to represent significant unmet medical needs in CRPC, we believe that CB7630 has strong potential in both of these patient populations." Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "We are pleased to be able to present data from both of these CB7630 trials at ESMO. We look forward to continuing to provide updates on these ongoing trials at future cancer conferences and greatly look forward to the continued development of CB7630 in both the second line hormone therapy and second line chemotherapy settings."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These forward-looking statements include, without limitation, statements related to benefits to be derived from Cougar's drug development programs, including the potential advantages of CB7630 and its potential for use in the treatment of CRPC and in
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:8/28/2015)... HILL, N.C. , Aug. 28, 2015 /PRNewswire/ ... market research projects can slow down the decision-making ... It is, therefore, absolutely critical for biopharmaceutical companies ... market research approval process for quicker and more ... research by Best Practices, LLC, nearly three-quarters of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... UPI ) announced today that it will release financial ... at the market close on Monday, November 2, 2009. ... results on Monday, November 2, 2009 at 3:30 p.m. Central ... Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will ...
... 21 Shire plc,(LSE: SHP, NASDAQ: SHPGY ), ... Biologics License Application (BLA) with the U.S.,Food and Drug ... for Fabry disease, by the end of the year. ... filed at the,request of FDA, has been approved, and ...
Cached Medicine Technology:Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 4
(Date:8/31/2015)... ... August 31, 2015 , ... The ... on the use of health IT to create efficiencies in healthcare information exchange, ... 2015 . Taking place at the Hyatt Regency Reston in Reston, Va. from ...
(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like ... director of GreenFields of Geneva. During his first days on the job, he’s run ... nice seeing them, and I like knowing that they’re living in such a wonderful ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Brooks Group, a global ... a department devoted to helping organizations identify and keep the best talent both ... The Brooks Group believes in offering a solution that goes beyond simply providing ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech ... Business Owners and provided a tour of their North American facility following the ... to international companies expanding business in the U.S. , The PartnerTech Inc. ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... According to ... Cancer Solution: Taking Charge of Your Life with Cancer is an excellent resource ... Santangeloon found The Cancer Solution to be helpful in explaining what cancer is in ...
Breaking Medicine News(10 mins):Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:PartnerTech Supports Economic Growth as Host 2Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2
... education bill in the state that allows private professional colleges ... ,Lok Sabha member Panniyan Ravindran, while talking to the Gulf ... said he would fight it. ,He was in ... anniversary of Kerala's former chief minister P.K. Vasudevan Nair. ...
... Bhopal and two of its doctors have been asked by ... for alleged// post-operative negligence resulting in the death of a ... Ayushman Hospital following swelling in her uterus and respiratory trouble. ... Since the tumor was not malignant and the possibility of ...
... Health Organization has communicated to countries the benefits of building ... 100 companies have sent in their request// to Roche AG, ... to combat a potential bird-flu pandemic. ,Though ... flu, yet they have enabled companies a list of things ...
... Health Canada has warned about the inherent risks involved ... ,The human milk is capable of ... There are chances that the human milk carries remnants ... consumed. Even unhygienic storage of milk, and not adhering ...
... care workers in the United States has risen, so ... ,According to Vanderbilt infectious disease experts Timothy ... should be provided to health care workers with latent ... test, particularly if they meet certain high-risk criteria. ...
... Pharma company Venus Remedies Ltd today said it ... its latest antibiotic fixed dose combination used in ... ,The new antibiotic combination, active against multi-resistant strains ... provides a broad-spectrum coverage of bactericidal activity, it ...
Cached Medicine News:
VACUETTE® Tube Holders should be used exclusively with VACUETTE® Blood Collection Needles as both components are designed for optimal compatibility with one another....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Less traumatic jaws offer a firm grasp while a self-retaining spring maintains hold on the needle. Use for grasping, applying endoloops, and driving needles during extracorporeal suturing....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: